---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-034341"
form_type: "8-K"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2022-06-22T23:59:59+00:00"
generated_at: "2026-06-25T00:05:47.455235+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pasithea acquires Alpha-5 integrin in $3.75M stock-and-warrant deal for ALS/neurology pipeline

## Summary
- Pasithea acquires all equity of Alpha-5; total consideration: 3,260,870 shares of KTTA common stock at $1.15/share (11% premium to June 21 close) plus 1M warrants at $1.88 exercise price for 5 years.
- Alpha-5 holds preclinical-stage anti-alpha-5 integrin mAb targeting ALS, MS, and other neuroinflammatory disorders; IND filing expected by end of 2023.
- Contingent earn-out of 2%–4% of net sales from Alpha-5's drug candidate if commercialized.
- Lawrence Steinman, Pasithea's Chairman and co-founder and minority Alpha-5 owner, recused from vote; deal approved by disinterested directors.
- Paul B. Manning (Alpha-5 majority owner) will own approximately 10% of Pasithea post-closing.

## SEC filing metadata
- accession: 0001213900-22-034341
- form_type: 8-K
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2022-06-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390022034341/0001213900-22-034341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390022034341/ea161902-8k_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-034341
- JSON: https://secwatch.observer/filing/0001213900-22-034341.json
- Plain text: https://secwatch.observer/filing/0001213900-22-034341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.